SHR-A1811 + carboplatin + bevacizumab

SHR-A1811 + carboplatin + bevacizumab is an experimental combination therapy under investigation for the treatment of HER2-positive and possibly other forms of breast cancer. SHR-A1811 is a third-generation antibody-drug conjugate (ADC) targeting HER2, designed to deliver a cytotoxic payload directly to HER2-expressing cancer cells, thereby enhancing tumor cell kill while limiting off-target toxicity[1][3][7]. Carboplatin is a platinum-based alkylating agent that induces DNA crosslinking, inhibiting DNA replication and transcription, which leads to apoptosis. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis, the process of new blood vessel formation critical for tumor growth[2][6][8]. The combination is not approved for clinical use and is being evaluated in clinical trials for efficacy and safety in HER2-positive breast cancer. Primary results indicate promising antitumor activity and acceptable tolerability for SHR-A1811, and bevacizumab’s established anti-angiogenic mechanism may enhance the combination’s effects[1][3][7].

Other names

SHR-A1811SHR-A-1811SHR-A 1811carboplatinbevacizumab